Close

Dermira (DERM) Announces CIMZIA Phase 3 Met co-Primary Efficacy Endpoints in Certain Plaque Psoriasis

December 8, 2016 6:18 AM EST Send to a Friend
UCB (Euronext: UCB) and Dermira, Inc. (Nasdaq: DERM) announced topline results from CIMPASI-1, a Phase 3, multi-center, placebo-controlled clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login